Riskpilot← Back to searchSign inGet full accessAntag Therapeutics ApS
APSActiveCVR 38402056Ole Maaløes Vej 3Manufacture of pharmaceutical preparations · NACE 2120Est. 201710 employeeshttp://www.antagtherapeutics.com/
Revenue 2024
DKK -30,6M
+123% vs 2023
EBITDA margin
109.0%
-108% vs 2023
Equity ratio
89.3%
Financial strength
Net profit 2024
DKK -32,3M
-134% vs 2023
| Revenue | DKK -30,6M | +123% |
| EBITDA | DKK -33,3M | -108% |
| Net profit | DKK -32,3M | -134% |
| Total assets | DKK 225,4M | +840% |
| Equity | DKK 201,2M | +2294% |
| Employees | 10 | — |
Legal name
Antag Therapeutics ApS
CVR number
38402056
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
8. februar 2017
Share capital
DKK 487.848
Employees
10 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to medlemmer af bestyrelsen i forening, af en direktør i forening med bestyrelsesformanden, eller af den samlede bestyrelse.
Company purpose
Selskabets formål er forskning og udvikling af lægemidler samt dermed beslægtet virksomhed.
Address
Ole Maaløes Vej 3
Phone
+4521456537
Email
antag@antagtherapeutics.com
Website
http://www.antagtherapeutics.com/
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -3.717 | -3.124 | -7.867 | -10.925 | -13.086 | -9.904 | -13.708 | -30.596 |
| Staff expenses | -947 | -2.528 | -3.493 | -3.693 | -2.652 | -1.502 | -2.291 | -2.742 |
| EBITDA | -4.664 | -5.651 | -11.359 | -14.618 | -15.738 | -11.406 | -15.999 | -33.339 |
| Depreciation & amort. | -0 | -0 | -13 | -27 | -34 | -34 | -33 | -13 |
| EBIT | -4.664 | -5.651 | -11.372 | -14.645 | -15.772 | -11.440 | -16.032 | -33.352 |
| Net financials | -30 | -35 | -464 | -328 | -1.687 | -558 | -939 | -4.054 |
| Profit before tax | -4.693 | -5.687 | -11.836 | -14.973 | -17.459 | -11.997 | -16.971 | -37.405 |
| Tax | -792 | -1.258 | -2.604 | -2.619 | -2.595 | -2.213 | -3.160 | -5.140 |
| Net profit | -3.902 | -4.429 | -9.232 | -12.353 | -14.863 | -9.784 | -13.811 | -32.265 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 10.087 | 12.714 | 14.116 | 15.721 | 20.671 | 17.564 | 23.970 | 225.361 |
| Equity | 8.708 | 11.816 | 2.584 | -9.769 | 10.858 | 4.639 | -9.173 | 201.235 |
| Long-term debt | 0 | 0 | 10.749 | 24.677 | 8.671 | 9.106 | 28.276 | 4.690 |
| Short-term debt | 1.378 | 897 | 783 | 813 | 1.143 | 3.819 | 4.867 | 19.436 |
| Total debt | 1.378 | 897 | 11.532 | 25.490 | 9.813 | 12.925 | 33.143 | 24.126 |
EBITDA margin
-3333854500.0%
This company
15.8%
Market median
-21100345037% vs market
20172024
Equity ratio
89.3%
This company
38.2%
Market median
+134% vs market
20172024
Return on equity
-16.0%
This company
18.4%
Market median
-187% vs market
20172024
Net profit margin
-3226524900.0%
This company
8.1%
Market median
-39833640841% vs market
20172024
Asset turnover
-0.14×
This company
1.12×
Market median
-113% vs market
20172024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20172024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-02-08 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MB Founder | Founder | 2017 | — | — |
JM Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
JJ Founder | Founder | 2017 | — | — |
AH Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
PJ Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
MM Founder | Founder | 2017 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2026 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 25.0% | 25.0% | 2026 | |
Novo Holdings A/S | Company | 20.0% | 20.0% | 2026 |
| Individual | 10.0% | 10.0% | 2026 | |
| Individual | 5.0% | 5.0% | 2026 | |
Danmarks Eksport- og Investeringsfond | Company | 5.0% | 5.0% | 2023 |
VÆKSTFONDEN | Company | 5.0% | 5.0% | 2021 |
| Individual | 5.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Antag Therapeutics ApS Board members of Antag Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Buur Nordskov Gabe | Founder | 0 companies |
| Jörg Möller | Chief Executive Officer | 0 companies |
| Jens Juul Holst | Founder | 0 companies |
| Alexander Hovard Sparre-Ulrich | Chief Executive Officer | 0 companies |
| Philip Just Larsen | Chief Executive Officer | 0 companies |
| Mette Marie Rosenkilde | Founder | 0 companies |
| Jørgen Søberg Petersen | Chairman | 0 companies |
| Mark Currie | Board of Directors | 0 companies |
| Emmanuelle Coutanceau | Board of Directors | 0 companies |
| Christine Theresa Fischette | Board of Directors | 0 companies |
| Pieter Jeroen Bakker | Board of Directors | 0 companies |
| Jayson Dallas | Board of Directors | 0 companies |
| Kirsten Aarup Drejer | Chairman | 0 companies |
| Anker Gunvald Lundemose | Board of Directors | 0 companies |
| Alexander Volker Wilhelm Mayweg | Board of Directors | 0 companies |
| Thomas Edward Needham Jr. | Board of Directors | 0 companies |
| Amit Kantilal Shah | Board of Directors | 0 companies |